» Articles » PMID: 27463374

Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection

Abstract

The RV254 cohort of HIV-infected very early acute (4thG stage 1 and 2) (stage 1/2) and late acute (4thG stage 3) (stage 3) individuals was used to study T helper- B cell responses in acute HIV infection and the impact of early antiretroviral treatment (ART) on T and B cell function. To investigate this, the function of circulating T follicular helper cells (cTfh) from this cohort was examined, and cTfh and memory B cell populations were phenotyped. Impaired cTfh cell function was observed in individuals treated in stage 3 when compared to stage 1/2. The cTfh/B cell cocultures showed lower B cell survival and IgG secretion at stage 3 compared to stage 1/2. This coincided with lower IL-10 and increased RANTES and TNF-α suggesting a role for inflammation in altering cTfh and B cell responses. Elevated plasma viral load in stage 3 was found to correlate with decreased cTfh-mediated B cell IgG production indicating a role for increased viremia in cTfh impairment and dysfunctional humoral response. Phenotypic perturbations were also evident in the mature B cell compartment, most notably a decrease in resting memory B cells in stage 3 compared to stage 1/2, coinciding with higher viremia. Our coculture assay also suggested that intrinsic memory B cell defects could contribute to the impaired response despite at a lower level. Overall, cTfh-mediated B cell responses are significantly altered in stage 3 compared to stage 1/2, coinciding with increased inflammation and a reduction in memory B cells. These data suggest that early ART for acutely HIV infected individuals could prevent immune dysregulation while preserving cTfh function and B cell memory.

Citing Articles

Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.

Muir R, Metcalf T, Fourati S, Bartsch Y, Kyosiimire-Lugemwa J, Canderan G PLoS Negl Trop Dis. 2023; 17(7):e0011089.

PMID: 37406029 PMC: 10351710. DOI: 10.1371/journal.pntd.0011089.


A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants.

Qin S, Huang H, Xiao W, Chen K, He X, Tang X Acta Pharm Sin B. 2023; .

PMID: 36647424 PMC: 9833852. DOI: 10.1016/j.apsb.2023.01.010.


Abnormal Shift in B Memory Cell Profile Is Associated With the Expansion of Circulating T Follicular Helper Cells ICOS Signaling During Acute HIV-1 Infection.

Lu X, Zhang X, Cheung A, Moog C, Xia H, Li Z Front Immunol. 2022; 13:837921.

PMID: 35222430 PMC: 8867039. DOI: 10.3389/fimmu.2022.837921.


Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.

Mitchell J, Pollara J, Dietze K, Edwards R, Nohara J, Nguessan K J Clin Invest. 2021; 132(1).

PMID: 34762600 PMC: 8718150. DOI: 10.1172/JCI150937.


Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.

Dias J, Fabozzi G, March K, Asokan M, Almasri C, Fintzi J J Clin Invest. 2021; 131(17).

PMID: 34623326 PMC: 8409578. DOI: 10.1172/JCI151632.


References
1.
Malaspina A, Moir S, Chaitt D, Rehm C, Kottilil S, Falloon J . Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood. 2006; 109(5):2086-8. PMC: 1801046. DOI: 10.1182/blood-2006-06-031385. View

2.
Ananworanich J, Dube K, Chomont N . How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?. Curr Opin HIV AIDS. 2014; 10(1):18-28. PMC: 4271317. DOI: 10.1097/COH.0000000000000122. View

3.
Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, Tassandin C . Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS. 2005; 19(17):1947-55. DOI: 10.1097/01.aids.0000191231.54170.89. View

4.
Locci M, Havenar-Daughton C, Landais E, Wu J, Kroenke M, Arlehamn C . Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013; 39(4):758-69. PMC: 3996844. DOI: 10.1016/j.immuni.2013.08.031. View

5.
Gianella S, Anderson C, Richman D, Smith D, Little S . No evidence of posttreatment control after early initiation of antiretroviral therapy. AIDS. 2015; 29(16):2093-7. PMC: 4638137. DOI: 10.1097/QAD.0000000000000816. View